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Methods: This was an observational study of 3041 STEMI patients treated with PPCI
between 2004 and 2011 at a single centre with follow-up for a median of 3.0 years (IQR
range: 1.2-4.6 years). The primary end-point was long-term all cause mortality and major
adverse cardiac events (MACE).
Results: There were 1044 (%) patients who underwent PPCI during ‘In-hours’’ (IHs)
compared to 1649 (%) patients ‘out-of-hours’ (OFHs). Baseline characteristics were
similar between the two groups. Over the follow-up there were significant differences in
rates of mortality (IHs 7.4% vs. OFHs 7.2%, p0.442) or MACE (IHs 15.4% vs. OFHs
14.1%, p0.192 - Figure 1) between the two groups. In addition, there were no significant
differences in door-to-balloon times between the two groups (IHs 67.8mins vs 69.6mins,
p0.709). After adjustment for confounding variables using multivariate analysis, OFHs
PPCI was not an independent predictor of mortality (HR 1.04 95% CI: 0.78-1.39). In
addition, door-to-balloon time was not an independent predictor of mortality (HR 1.43
95% CI: 0.94-2.16).
Conclusions: Patients undergoing PPCI during ‘out-of-hours’ have similar outcomes to
patients undergoing PPCI during ‘In-hours’. In addition, we did not find any significant
delay in door-to-balloon times in the ‘out-of-hours’ group. This data adds to the growing
literature suggesting ‘out-of-hours’ PPCI is safe.
TCT-507
Left bundle branch block activations for primary percutaneous coronary
intervention: non-specific finding or a marker for increased mortality?
Adam Brown1, Paul Cacciottolo1, Matt Malone-Lee1, Liam McCormick1,
Peter Schofield1, Stephen Hoole1, Nick West1
1Papworth Hospital, Cambridge, United Kingdom
Background: The activation criteria for primary percutaneous coronary intervention
(PPCI) includes chest pain in association with either ST-segment elevation (STE) or
new-onset left bundle branch block (LBBB) on the ECG. However, defining LBBB as
new is challenging acutely and the poor specificity of indeterminate chronicity LBBB may
result in unnecessary PPCI activations. Published data are conflicting with regard to the
utility of LBBB as a triage criterion for PPCI and the subsequent outcomes are undefined.
Methods: Consecutive patients attending a single UK tertiary centre for presumed PPCI
between September 2008 and December 2011 were included (n2192). The activation ECG
was obtained from the hospital PPCI database, as were demographic data. Outcome data were
obtained from notes and national databases. MACE was defined as a composite of mortality
and unplanned revascularisation. Two interventionists blinded to patient outcome reviewed the
angiographic images and adjudicated if the activation was appropriate.
Results: Chest pain with LBBB (LBBB-activation) occurred in 120 patients (5.5%) of
the overall PPCI cohort. Comparing LBBB-activations to those with STE demonstrated
that LBBB-activations were older (mean age 70.712.2 vs 64.613.4 yrs; p0.001) and
less likely to be male (66.7% vs 76.8%; p0.004). Other baseline demographics were
similar. 21 (17.5%) patients presenting with LBBB-activation had an acute thrombotic
coronary occlusion confirmed at angiography and received PPCI. The final adjudicated
diagnoses for LBBB-activations were acute coronary syndrome (ACS) (39.2%), non-ACS
cardiac (33.3%) and non-cardiac (27.5%). One-year mortality and MACE were higher for
appropriate LBBB-activations than the STEMI activations (31.3% vs 7.2%, p0.002 and
40.0% vs 11.9%, p0.007 respectively).
Conclusions: Less than half of LBBB-activations had an ACS and, of these, only half
had a thrombotic coronary occlusion requiring PPCI. However, LBBB-activations have a
significantly worse prognosis and merit urgent referral. Enhanced triage methods are
required to correctly identify acute MI requiring PPCI in those with LBBB.
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Background: There is a paucity of evidence on the optimal medical therapy in patients
with hypertension and acute myocardial infarction (MI) particularly on the role of calcium
channel blockers (CCB).
Methods: A total of 5,076 hemodynamically stable patients who underwent primary PCI
for ST-elevation MI within 12 hours after symptom onset were dichotomized according
to the presence of antecedent hypertension. Benefit of angiotensin-converting enzyme
inhibitors (ACEI) or angiotensin-receptor blockers (ARB), beta blockers, CCB, and
diuretics administered during hospitalization was compared between the 2 groups during
12-month follow-up.
Results: Patients with hypertension (n  2,229, 43.9%) had higher in-hospital mortality
(2.2% vs. 1.1%, p  0.02), but adjusted 12-month rates of death and death/MI were not
statistically different between the groups. ACEI/ARB reduced 12-month mortality both in
patients with hypertension (hazard ratio [HR] 0.34, 95% confidence interval [CI]
0.22-0.53, p  0.001) and in patients without hypertension (HR 0.39, 95% CI 0.24-0.64,
p  0.001). Beta blocker therapy significantly reduced 12-month mortality in patients
with hypertension (HR 0.55, 95% CI 0.34-0.90, p  0.02). In contrast, use of CCB and
diuretics was associated with increased 12-month mortality in patients with hypertension
(HR 2.09, 95% CI 1.19-3.66, p  0.01 and HR 2.03, 95% CI 1.31-3.16, p  0.002,
respectively).
Conclusions: In patients with hypertension undergoing primary PCI for ST-elevation
MI, in-hospital mortality was higher and use of CCB and diuretics was associated with
increased 12-month mortality, compared to patients without hypertension.
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Background: Distal embolization (DE) is a major contributor to no-reflow and greater
myocardial necrosis in STEMI. Manual Aspiration Thrombectomy (MAT) may reduce
intra-procedural thrombotic complications, DE and improve procedural and clinical
outcomes. Whether these findings are applicable to contemporary interventional practice
is unknown.
Methods: The INFUSE-AMI trial randomized 452 pts with anterior STEMI due to prox
or mid LAD occlusion, treated with bivalirudin, to intracoronary bolus abciximab
delivered locally via the ClearWay RX catheter vs. no abciximab, and to MAT with the
Export catheter vs. no MAT. The primary endpoint was core laboratory assessed MRI
infarct size (IS, % of LV mass) at 30 days. Presence of thrombus and DE were assessed
at an independent angiographic core laboratory.
Results: Median age was 61y, 74% were men and 11% had diabetes. Intracoronary
abciximab reduced median IS: 15.1 [6.8-22.7] vs. 17.9 [10.3-25.4], P0.03, whereas
MAT did not. Thrombus was present at baseline in 85.8% and 87.0% of the MAT and no
MAT groups, respectively (P0.7), and thrombus area was 19.45  11.04 and 20.27 
11.89 mm2 (P0.55). Balloon pre-dilatation was performed in 47.5% of MAT and 66.7%
of no MAT (P0.0001). Immediately pre-stenting, thrombus was present in 48.8% and
66.9% of MAT and no MAT (P0.0004). Similarly, thrombus area was reduced with
MAT vs. no MAT (11.68 8.17 vs 15.43 9.73 mm2), P0.008. DE was seen in 1.7%
(4/232) and 3.6% (8/223) of MAT and no MAT (P0.22). There were no significant
differences between MAT and no MAT with regard to TIMI flow grades or myocardial
blush grades at baseline or post stenting. These parameters, however, were worse in no
MAT immediately before stenting: TIMI 0/1 13.6% vs. 38.7%; MBG 0/1 22.6% vs.
48.0%, for MAT and no MAT (P0.0001 for both).
Conclusions: In the INFUSE-AMI trial, the incidence of DE in pts undergoing stenting
for STEMI was low and not influenced by use of MAT. MAT resulted in smaller
thrombus burden and better intra-procedural myocardial perfusion pre-stenting compared
to no MAT, but this advantage was lost after stenting. These findings offer mechanistic
insights into why MAT failed to reduce infarct size in the INFUSE-AMI trial.
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